© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
September
Study Supports Feasibility of Routine Molecular Screening of NSCLC in Community Setting
September 21, 2012
Article
Evidence-Based Oncology
Oncology Leaders Praise Health Law Ruling-With Caveats
September 20, 2012
Article
Evidence-Based Oncology
Down the Road for Breast Cancer
September 20, 2012
Article
Evidence-Based Oncology
Targeted Therapies to Further Improve Outcomes
How Payers and Oncologists Really Feel About Oncology Pathways
September 20, 2012
Article
Evidence-Based Oncology
Partnering With a Payer to Develop a Value-Based Medical Home Pilot: A West Coast Practice's Experience
September 20, 2012
Article
Evidence-Based Oncology
Rationalizing Treatment and Coverage Decisions With Predictive Biomarkers
September 18, 2012
Article
Evidence-Based Oncology
Trends in the 2012 Eisai Oncology Digest: Counseling and Communication of Cancer Treatment
September 18, 2012
Article
Evidence-Based Oncology
The Keys to Obtaining Best Value in Non-Small Cell Lung Cancer
September 18, 2012
Article
Evidence-Based Oncology
Achieving Quality and Containing Cost Through Oncology Pharmacy Management
September 17, 2012
Article
Evidence-Based Oncology
Treatment and Cost Implications of Pertuzumab
September 17, 2012
Article
Evidence-Based Oncology
Michael E. Chernew, PhD; Lee N. Newcomer, MD, MHA; and Sandra M. Swain, MD; examine the treatment benefits, cost concerns, and insurance coverage strategies for pertuzumab.
Trends in the 2012 Eisai Oncology Digest: Counseling and Communication of Cancer Treatment
August 17, 2012
Article
Evidence-Based Oncology